IL6R and ovarian carcinoma: A second phase I/II trial in ovarian cancer investigated the combination of the ICD inducing chemotherapeutics carboplatin or doxorubicin in combination with tocilizumab, an anti-IL-6R antibody, and pegylated IFN-⍺ (NCT01637532).